To Our Shareholders
and Investors

• July 14, 2025

  R & D
  CAP-1002: Capricor Therapeutics received Complete Response Letter from the U.S. FDA for Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy
• July 03, 2025

  Management & Finance
  Nippon Shinyaku Selected as a Constituent of the SOMPO Sustainability Index
• July 01, 2025

  R & D
  Announcement of Strategic Alliance with Boston Children's Hospital
• May 14, 2025

  R & D
  RGX-121 (clemidsogene lanparvovec) : The U.S. FDA has accepted the Biologics License Application by REGENXBIO for Mucopolysaccharidosis II Disease

Upcoming Events

• August 07, 2025

  Conference Call(Q1/FY2025)

• August 07, 2025

  FY2025 1st Qtr results announcement

• May 08, 2025
  IR Meeting (Q4/FY2024) PDF1 MB
• May 08, 2025
  FY2024 Annual results announcement PDF1.9 MB
• February 18, 2025
  R&D Meeting PDF1.7 MB